The goal of this clinical trial is to test the safety and effectiveness of a single dose of RABI-767 given by endoscopic ultrasound (EUS) guided peripancreatic injection in participants with predicted severe acute pancreatitis. The main question the study aims to answer is: • Is a single-dose of RABI-767 given by EUS-guided peripancreatic injection safe in patients with predicted severe acute pancreatitis. The study also aims to answer: • Is a single-dose of RABI-767 given by EUS-guided peripancreatic injection effective in treating patients with predicted severe acute pancreatitis. Study participants will be randomly assigned (like the flip of a coin) to receive a single dose of RABI-767 plus supportive care or supportive care only. The study sponsor will compare safety and efficacy data collected from participants who receive RABI-767 to participants who receive supportive care only to test if RABI-767 is safe and effective.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants with Adverse Events
Timeframe: Enrollment/Randomization to Day 28 (or hospital discharge, if earlier)
Number of Participants with Serious Adverse Events
Timeframe: Enrollment/Randomization to Day 35 Follow-up
Change from Baseline in Clinical Chemistry Parameters
Timeframe: Baseline to Day 7
Change from Baseline in Hematology Parameters
Timeframe: Baseline to Day 7
Change from Baseline in Vital Signs
Timeframe: Baseline to Day 7
Change from Baseline in Pulse Oximetry and Oxygen Delivery Measurements
Timeframe: Baseline to Day 7